NO20003785L - Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon - Google Patents

Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon

Info

Publication number
NO20003785L
NO20003785L NO20003785A NO20003785A NO20003785L NO 20003785 L NO20003785 L NO 20003785L NO 20003785 A NO20003785 A NO 20003785A NO 20003785 A NO20003785 A NO 20003785A NO 20003785 L NO20003785 L NO 20003785L
Authority
NO
Norway
Prior art keywords
prevention
benzothiazole
trifluoromethoxy
therapy
amino
Prior art date
Application number
NO20003785A
Other languages
English (en)
Other versions
NO20003785D0 (no
NO327819B1 (no
Inventor
Andrees Bohme
Alain Boireau
Thierry Canton
Assunta Imperato
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20003785L publication Critical patent/NO20003785L/no
Publication of NO20003785D0 publication Critical patent/NO20003785D0/no
Publication of NO327819B1 publication Critical patent/NO327819B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20003785A 1998-02-06 2000-07-24 Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav NO327819B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (3)

Publication Number Publication Date
NO20003785L true NO20003785L (no) 2000-07-24
NO20003785D0 NO20003785D0 (no) 2000-07-24
NO327819B1 NO327819B1 (no) 2009-09-28

Family

ID=9522673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003785A NO327819B1 (no) 1998-02-06 2000-07-24 Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav

Country Status (18)

Country Link
US (1) US6245791B1 (no)
EP (1) EP1052989B1 (no)
JP (1) JP5127092B2 (no)
KR (1) KR100574378B1 (no)
AT (1) ATE245982T1 (no)
AU (1) AU761978B2 (no)
CA (1) CA2319686C (no)
DE (1) DE69909970T2 (no)
DK (1) DK1052989T3 (no)
EA (1) EA002676B1 (no)
ES (1) ES2199541T3 (no)
FR (1) FR2774592B1 (no)
IL (2) IL137608A0 (no)
NO (1) NO327819B1 (no)
NZ (1) NZ506124A (no)
PT (1) PT1052989E (no)
WO (1) WO1999039710A1 (no)
ZA (1) ZA99740B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
EP3265448B1 (en) * 2015-03-03 2021-12-29 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
FI3706739T3 (fi) * 2017-11-12 2024-12-27 Biohaven Therapeutics Ltd Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi
CN112203692A (zh) * 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68901859T2 (de) * 1988-12-15 1993-01-14 Rhone Poulenc Sante 2-benzothiazolamin-derivate enthaltende arzneimittel, verbindungen und ihre herstellung.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
CA2319686C (fr) 2009-06-23
ES2199541T3 (es) 2004-02-16
FR2774592B1 (fr) 2000-03-17
US6245791B1 (en) 2001-06-12
AU761978B2 (en) 2003-06-12
KR20010040671A (ko) 2001-05-15
AU2171199A (en) 1999-08-23
ATE245982T1 (de) 2003-08-15
EA002676B1 (ru) 2002-08-29
EP1052989B1 (fr) 2003-07-30
NZ506124A (en) 2003-07-25
JP2002502819A (ja) 2002-01-29
IL137608A (en) 2006-09-05
ZA99740B (en) 1999-08-02
DE69909970T2 (de) 2004-05-27
EA200000816A1 (ru) 2001-02-26
EP1052989A1 (fr) 2000-11-22
DK1052989T3 (da) 2003-11-17
IL137608A0 (en) 2001-07-24
CA2319686A1 (fr) 1999-08-12
NO20003785D0 (no) 2000-07-24
DE69909970D1 (de) 2003-09-04
PT1052989E (pt) 2003-12-31
WO1999039710A1 (fr) 1999-08-12
JP5127092B2 (ja) 2013-01-23
FR2774592A1 (fr) 1999-08-13
NO327819B1 (no) 2009-09-28
KR100574378B1 (ko) 2006-04-26

Similar Documents

Publication Publication Date Title
GB0225475D0 (en) Therapeutic agents
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
AP2005003350A0 (en) 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases.
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
NO20005290L (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
BG106293A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
BR0214020A (pt) Método para tratar fibrose cìstica
NO20003785D0 (no) Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon
DK0683170T3 (da) Glucopyranosidbenzothiophener
EE200100663A (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
BR0007395B1 (pt) compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias.
SE9602416D0 (sv) New forms of an organic salt of N'N-diacetylcystine
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
PA8505301A1 (es) Metodo para tratar el mal de parkinson a traves de la administracion de ( - ) - 5 ceto-2-n- propilamino - tetrahidrotetralina
SE9501773D0 (sv) New use
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees